RNS Number : 4566J
Redx Pharma plc
13 December 2022

REDX PHARMA PLC

("Redx" or the "Company")

Notice of Preliminary Results

Alderley Park, UK, 13 December 2022 - Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, will be releasing its preliminary results for the full year ended 30 September 2022 on 20 December 2022.

A live webcast for analysts and investors will be held at 12:00 GMT (07:00 ET) on 20 December 2022. To join the webcast, please register in advance by sending an email to redxpharma@fticonsulting.com.

A recording of the webcast will be made available on Redx's website following the results meeting at https://www.redxpharma.com/investor-centre/.

For further information, please contact:

Redx Pharma Plc **UK Headquarters** Caitlin Pearson, Head of Communications ir@redxpharma.com	T: +44 (0)1625 469 918
Lisa Anson, Chief Executive Officer	
US Office Peter Collum, Chief Financial Officer	
SPARK Advisory Partners (Nominated Adviser) Matt Davis/ Adam Dawes	T: +44 (0)203 368 3550
WG Partners LLP (Joint Broker) Claes Spång/ Satheesh Nadarajah/ David Wilson	T: +44 (0)203 705 9330
Panmure Gordon (UK) Limited (Joint Broker) Rupert Dearden/ Freddy Crossley/ Emma Earl	T: +44 (0)207 886 2500
FTI Consulting Simon Conway/ Ciara Martin	T: +44 (0)203 727 1000

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-dependent cancers, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics

against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

END

NORFFFSLFELFLIF